Status:
COMPLETED
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Acute Gouty Arthritis Flares
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combi...
Eligibility Criteria
Inclusion
- Patients who have completed the second extension studies CACZ885H2356E2 or CACZ885H2357E2
- Patients treated with canakinumab in the core studies or subsequent extensions
Exclusion
- \- Pregnant or nursing (lactating) women
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT01470989
Start Date
November 1 2011
End Date
May 1 2013
Last Update
July 9 2021
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Anniston, Alabama, United States, 36207-5710
2
Novartis Investigative Site
Mobile, Alabama, United States, 36608
3
Novartis Investigative Site
Norwalk, California, United States, 90650
4
Novartis Investigative Site
Pasadena, California, United States, 91105